TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 375376

Group type: EXPERIMENTAL
Intervention: 15(R)15 methyl prostaglandin E2 (free acid) at doses of 80, 140, 200, and 400 micrograms
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 15(R)15 methyl prostaglandin E2 (methylester) at doses of 80, 140, and 200 micrograms
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of 80 micrograms methyl ester and 1.5 mg atropine sulphate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 11
Study: 31189680

Group type: EXPERIMENTAL
Intervention: NeuroSAFE RALP
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard RALP
Number of subjects: 50
Study: 27528118

Group type: EXPERIMENTAL
Intervention: 40 Gy (experimental arm)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 50 Gy (control arm)
Number of subjects: 200
Study: 25975643

Group type: EXPERIMENTAL
Intervention: Multidisciplinary QOL-directed intervention (exercise, education, relaxation sessions, 6 to 8 sessions bi- to triweekly)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Multidisciplinary QOL-directed intervention
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Multidisciplinary QOL-directed intervention (for those undergoing neoadjuvant therapy)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual medical care (control group, for those undergoing neoadjuvant therapy)
Number of subjects: 61
Study: 23971512

Group type: EXPERIMENTAL
Intervention: 5 A's smoking cessation intervention delivered by trained midwives in 10 intervention clinics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard in-service activities in 10 control clinics
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5 A's smoking cessation intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard in-service activities
Number of subjects: 20
Study: 21721962

Group type: EXPERIMENTAL
Intervention: Adherence Promotion (AP) intervention
Number of subjects: 434

Group type: COMPARATOR
Intervention: Cancer control condition
Number of subjects: 434
Study: 19545384

Group type: EXPERIMENTAL
Intervention: Patient Perception of Study Medication (PPSM) questionnaire
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: PPSM-Global and PPSM-Pain factors
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: PPSM
Number of subjects: 879
Study: 16677266

Group type: EXPERIMENTAL
Intervention: Clonidine (2 microg.kg(‐1) intravenously)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (intravenously)
Number of subjects: 120
Study: 15100619

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (24 g/day of white wine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: White grape juice (control)
Number of subjects: 18
Study: 11778969

Group type: EXPERIMENTAL
Intervention: Sequential therapy (ST) with infusional chemotherapy (IC) using VAMP/C-VAMP followed by autologous transplantation and interferon maintenance
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: High-dose therapy consolidation
Number of subjects: 251

Group type: COMPARATOR
Intervention: Cox analysis variables
Number of subjects: 251
Study: 9314107

Group type: EXPERIMENTAL
Intervention: Fetal movement
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control measurement by a blinded examiner
Number of subjects: 82
Study: 8419199

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg on days 2 to 6 of the menstrual cycle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cyclofenil 400 mg on days 3 to 12 of the menstrual cycle
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal ovulatory cycles (Control)
Number of subjects: 30
Study: 2868873

Group type: EXPERIMENTAL
Intervention: High-molecular elemental diet (diet 1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Low-molecular elemental diet (diet 2)
Number of subjects: 26
Study: 30500336

Group type: EXPERIMENTAL
Intervention: Self-administered lidocaine gel 2% 20mL intravaginally 15-30min before procedure initiation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lidocaine 1% 12mL paracervical block immediately prior to dilator placement
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Self-administered lidocaine gel
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lidocaine paracervical block
Number of subjects: 72
Study: 30367608

Group type: EXPERIMENTAL
Intervention: Smartphone-based automated feedback about ambulatory assessed early warning signs
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group without feedback
Number of subjects: 120
Study: 27465818

Group type: EXPERIMENTAL
Intervention: Tong Luo Hua Shi (TLHS) 4.8 g/day
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Tong Luo Hua Shi (TLHS) 3.6 g/day
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 24576156

Group type: EXPERIMENTAL
Intervention: Interferon beta 1b (IFN B 1B)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Natalizumab (NTZ)
Number of subjects: 19
Study: 22999634

Group type: COMPARATOR
Intervention: Prompt laser treatment
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Deferred laser treatment
Number of subjects: 361
Study: 20478865

Group type: EXPERIMENTAL
Intervention: Passive Smoking (PS) exposure for 1 hour
Number of subjects: 17
Study: 17629158

Group type: EXPERIMENTAL
Intervention: 500 mg of cefaclor twice daily for five to seven days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 750 mg of cefaclor three times daily for five to seven days
Number of subjects: 63
Study: 16209246

Group type: COMPARATOR
Intervention: IL-1ra serum concentration
Number of subjects: 27

Group type: COMPARATOR
Intervention: IL-1ra urinary excretion
Number of subjects: 27

Group type: COMPARATOR
Intervention: sTNFR I serum concentration
Number of subjects: 27

Group type: COMPARATOR
Intervention: sTNFR I urinary excretion
Number of subjects: 27

Group type: COMPARATOR
Intervention: sTNFR II serum concentration
Number of subjects: 27

Group type: COMPARATOR
Intervention: sTNFR II urinary excretion
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: sIL-1ra serum concentration
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: uIL-1ra urinary excretion
Number of subjects: 27
Study: 11931374

Group type: EXPERIMENTAL
Intervention: Fibrinogen adsorption treatment (4 treatments for healthy subjects, 144 treatments for patients)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fibrinogen adsorption treatment
Number of subjects: 18
Study: 10408327

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program for 9 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 30
Study: 8749600

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Progestogen-only pill (POP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 2390880

Group type: EXPERIMENTAL
Intervention: 30 mg daily
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 50 mg daily
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 300 mg daily
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 500 mg daily
Number of subjects: 345

Group type: COMPARATOR
Intervention: 0 mg (control)
Number of subjects: 345
Study: 6117302

Group type: EXPERIMENTAL
Intervention: Intravenous rimiterol (1050 microgram cumulative dose over 90 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aerosol rimiterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous rimiterol
Number of subjects: 12
Study: 31557763

Group type: EXPERIMENTAL
Intervention: Aspirin plus ticagrelor for 1 month followed by 23-month ticagrelor monotherapy
Number of subjects: 7487

Group type: COMPARATOR
Intervention: Aspirin plus either clopidogrel or ticagrelor for 12 months followed by 12-month aspirin monotherapy
Number of subjects: 7487
Study: 28139362

Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation (RNI) - 50 Gy
Number of subjects: 2106

Group type: COMPARATOR
Intervention: Completion axillary lymph node dissection (cALND) - standard treatment
Number of subjects: 2106
Study: 25884949

Group type: EXPERIMENTAL
Intervention: DXSCNP classifier
Number of subjects: 169

Group type: COMPARATOR
Intervention: DXCLINICAL2 classifier
Number of subjects: 169
Study: 23430349

Group type: EXPERIMENTAL
Intervention: Limberg flap (LF)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Modified Limberg flap (MLF)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Karydakis flap (KF)
Number of subjects: 295
Study: 22527920

Group type: EXPERIMENTAL
Intervention: Anal cooler
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no cooler)
Number of subjects: 100
Study: 19953915

Group type: EXPERIMENTAL
Intervention: Dexamethasone, 10 mg IV (Group D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 120 mg IV (Group M)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline, 10 ml IV (Group S)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between Group D and Group M
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between Group D and Group S
Number of subjects: 30
Study: 17329696

Group type: EXPERIMENTAL
Intervention: rHEV vaccine
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 16272454

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy and adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel molecular targeted therapies (trastuzumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomic profiling
Number of subjects: 0
Study: 11835924

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 3987

Group type: COMPARATOR
Intervention: Ibuprofen 800 mg 3 times daily or diclofenac 75 mg twice daily
Number of subjects: 3987

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 3987

Group type: COMPARATOR
Intervention: NSAIDs (combined or individually)
Number of subjects: 3987
Study: 10800498

Group type: EXPERIMENTAL
Intervention: Cytokine therapy (interferon-alpha)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokine therapy (interleukin-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapies (cytotoxic chemotherapies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy approaches
Number of subjects: 0
Study: 7675377

Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline infusion
Number of subjects: 52

Group type: COMPARATOR
Intervention: Laminaria
Number of subjects: 52
Study: 1688980

Group type: COMPARATOR
Intervention: Nifedipine (0.3 micrograms/kg/min infusion)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Enoximone (0.5 mg/kg bolus)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nifedipine and Enoximone (same dosages as above)
Number of subjects: 45
Study: 6784924

Group type: EXPERIMENTAL
Intervention: Mannitol (37.5 g by 6-hour infusion)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Furosemide (40 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2 every 21-28 days)
Number of subjects: 22
Study: 31599637

Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (PPT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 70
Study: 29233720

Group type: EXPERIMENTAL
Intervention: Northwestern Medical Group‐ Transitional Care (NMG‐TC) care model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 26547100

Group type: EXPERIMENTAL
Intervention: REG1 (pegnivacogin 1 mg/kg bolus followed by 80% reversal with anivamersen)
Number of subjects: 3232

Group type: COMPARATOR
Intervention: Bivalirudin
Number of subjects: 3232

Group type: EXPERIMENTAL
Intervention: REG1
Number of subjects: 3232
Study: 24935230

Group type: EXPERIMENTAL
Intervention: Group AB
Number of subjects: 13627

Group type: COMPARATOR
Intervention: Packed red blood cells (transfusion)
Number of subjects: 13627
Study: 22133650

Group type: EXPERIMENTAL
Intervention: Verapamil-sustained-release-led (Ve-led) treatment strategy
Number of subjects: 1019

Group type: COMPARATOR
Intervention: Atenolol-led (At-led) treatment strategy
Number of subjects: 1019
Study: 20060711

Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 564

Group type: COMPARATOR
Intervention: No Tamoxifen
Number of subjects: 564
Study: 18337008

Group type: EXPERIMENTAL
Intervention: AMG 517 (TRPV1 antagonist)
Number of subjects: 0
Study: 16508298

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 4 weeks, 10 mg/day thereafter)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo (delayed‐start group)
Number of subjects: 286
Study: 14624937

Group type: EXPERIMENTAL
Intervention: 2.0 g/kg/d protein feeding regime
Number of subjects: 50

Group type: COMPARATOR
Intervention: Escalating isocaloric protein feeding regime (1.5, 2.0, and 2.5 g/kg/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2.5 g/kg/d protein intake
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (if enteral feeding not tolerated)
Number of subjects: 50
Study: 11965831

Group type: EXPERIMENTAL
Intervention: Cholesterol lowering therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy with aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved glycaemic control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (pioglitazone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multifactorial approach (including improved glycaemic control, aggressive management of dyslipidaemia and hypertension, anti-platelet therapy, reduction of insulin resistance)
Number of subjects: 0
Study: 8911881

Group type: EXPERIMENTAL
Intervention: Fenoterol at 0.5 micrograms.min-1
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fenoterol at 1.0 micrograms.min-1
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fenoterol at 2.0 micrograms.min-1
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1922250

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2 g per day of elemental calcium in the form of calcium carbonate)
Number of subjects: 1194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (for women with low urinary calcium to creatinine ratio)
Number of subjects: 1194

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (for women with high urinary calcium to creatinine ratio)
Number of subjects: 1194
Study: 7084267

Group type: EXPERIMENTAL
Intervention: Bicycle and arm‐assisted step test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treadmill
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Arm‐assisted step test
Number of subjects: 12
Study: 30697793

Group type: EXPERIMENTAL
Intervention: Video-supported nurse-led advance care planning program
Number of subjects: 298

Group type: COMPARATOR
Intervention: Health education program at home
Number of subjects: 298
Study: 28327089

Group type: EXPERIMENTAL
Intervention: De-escalation of elective radiation dose with introduction of an intermediate dose-level for selected lymph nodes.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard elective radiation dose without de-escalation.
Number of subjects: 300
Study: 26489756

Group type: EXPERIMENTAL
Intervention: Guided self-help (GSH) based on cognitive behaviour therapy (CBT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard outpatient department support (Control)
Number of subjects: 54
Study: 23371748

Group type: EXPERIMENTAL
Intervention: Cognitive loading during walking
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cognitive loading during standing
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cognitive loading during cycling
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cognitive loading during all tasks
Number of subjects: 54
Study: 21234579

Group type: EXPERIMENTAL
Intervention: Choline citrate (300.2 mg intravenously every 12 hours until defecation)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (sodium chloride, every 12 hours until defecation)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Laparotomy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Choline citrate
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 19147459

Group type: EXPERIMENTAL
Intervention: Canrenone
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 17306222

Group type: EXPERIMENTAL
Intervention: Internet administration of the Obsessive Compulsive Inventory and the Obsessive Beliefs Questionnaire-44
Number of subjects: 0
Study: 15469788

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once a day
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no pravastatin)
Number of subjects: 71
Study: 11567815

Group type: EXPERIMENTAL
Intervention: EGFR overexpression (positive immunoreactivity)
Number of subjects: 170

Group type: COMPARATOR
Intervention: No EGFR immunoreactivity
Number of subjects: 170

Group type: COMPARATOR
Intervention: Intermediate EGFR staining
Number of subjects: 170

Group type: COMPARATOR
Intervention: Strong EGFR staining
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: p53 immunoreactivity or mutation status
Number of subjects: 170
Study: 9586915

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation therapy with warfarin (regimen I)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Chemotherapy and radiation therapy without warfarin (regimen II)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: ACE chemotherapy
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: PCE chemotherapy and RT
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Emotional state (POMS)
Number of subjects: 295
Study: 8139830

Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 24
Study: 3144199

Group type: EXPERIMENTAL
Intervention: Isotonic disodium cromoglycate (DSCG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hypotonic disodium cromoglycate (DSCG)
Number of subjects: 21
Study: 31420057

Group type: EXPERIMENTAL
Intervention: Oral Nigella sativa oil (1000 mg per capsule, 2 capsules per day for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (2 capsules per day for 8 weeks)
Number of subjects: 0
Study: 27347857

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) combined with eccentric training
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham shockwave combined with eccentric training
Number of subjects: 52
Study: 25733157

Group type: EXPERIMENTAL
Intervention: GS-9620 (0.3mg, 1mg, 2mg, 4mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GS-9620
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23541281

Group type: EXPERIMENTAL
Intervention: Maintenance percutaneous transluminal angioplasty (PTA) of nonthrombosed AVFs
Number of subjects: 69

Group type: COMPARATOR
Intervention: Maintenance percutaneous transluminal angioplasty (PTA) of nonthrombosed AVGs
Number of subjects: 69
Study: 22026565

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (average 6 hours over 6 months)
Number of subjects: 730

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 730
Study: 19192982

Group type: EXPERIMENTAL
Intervention: Romiplostim (intervention group)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 125
Study: 16737374

Group type: EXPERIMENTAL
Intervention: Awareness of in-group's mass killing of the out-group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of collective responsibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collective guilt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological strategies
Number of subjects: 0
Study: 15270928

Group type: EXPERIMENTAL
Intervention: Home-based postnatal care (n=228)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Hospital-based postnatal care (n=231)
Number of subjects: 459
Study: 11903702

Group type: EXPERIMENTAL
Intervention: Occupational therapy assessment and appropriate treatments/equipment before release
Number of subjects: 39

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 39
Study: 9346275

Group type: EXPERIMENTAL
Intervention: 100 microg vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 microg vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alum placebo
Number of subjects: 0
Study: 7946857

Group type: EXPERIMENTAL
Intervention: Fentanyl 2-ng ml-1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl 1-ng ml-1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no fentanyl)
Number of subjects: 30
Study: 3363295

Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 0
Study: 29456871

Group type: EXPERIMENTAL
Intervention: Behaviour change intervention for midwives (face-to-face training plus information resources)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 30
Study: 27547135

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell (BMC) injections
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cell‐free injections of a placebo
Number of subjects: 86
Study: 25911076

Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24053892

Group type: EXPERIMENTAL
Intervention: Ranibizumab injections
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ranibizumab injections + laser photocoagulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation between retinal nonperfusion area and BCVA
Number of subjects: 40
Study: 21126238

Group type: EXPERIMENTAL
Intervention: Inhalation induction with sevoflurane (S 1.5, 2.0, 2.5, 3.0)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (C) with 2.5% thiopental 5 mg/kg
Number of subjects: 75
Study: 18773841

Group type: EXPERIMENTAL
Intervention: Recommendations for interventions to prevent occupational disabilities
Number of subjects: 0